Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome
NCT05126563
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
79
Enrollment
INDUSTRY
Sponsor class
Conditions
Post COVID-19 Syndrome
Interventions
BIOLOGICAL:
HB-adMSCs (allogeneic)
OTHER:
Placebo
Sponsor
Hope Biosciences Research Foundation